Stem cell transplant versus more treatment for high-risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two approaches for adults with high-risk acute myeloid leukemia (AML) who have had one round of chemo. One option is a stem cell transplant from a donor (using someone else's cells to rebuild your bone marrow), and the other is more chemotherapy or other treatments. The goal is to see which approach works better for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have high-risk AML and have completed one round of induction chemo.
- You are willing to consider a stem cell transplant from a donor (related or unrelated).
- You are physically active enough to do daily tasks (Karnofsky score above 60).
- You have not had a stem cell transplant before.
- AML has not spread to your brain or spinal fluid, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests a specific transplant method using a half-matched donor to treat high-risk acute myeloid leukemia (AML), a type of blood cancer. It aims to reduce complications and improve outcomes for patients who have not responded to other treatments.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.